Fight Kids Cancer is a European association consortium which launched a call for projects at the end of 2019 to support research in the field of childhood cancer.Twenty-three research projects were submitted by various European researchers between mid-January and the end of April 2020. Six projects, particularly innovative and promising, were selected, including the one submitted by the CONECT-AML research teams.
ALARM 3 is a translational research project on pediatric acute myeloid leukemia (AML), which has a relapse rate of 35-45% with only 38% 4-year survival after relapse. It aims to compare the molecular profile of pediatric AML at diagnosis and relapse. By identifying new biological markers, the aim is to better identify the AMLs at greatest risk for relapse and to better understand the mechanism of resistance to treatment. The hope of this research is to achieve the integration of new targeted therapies as early as possible in treatment to reduce the risk of relapse. By reducing the risk of relapse, the indications for hematopoietic stem cell transplantation could decrease, making it possible to reduce the long-term sequelae of this treatment and thus improve the quality of life of cured patients.